Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)
نویسندگان
چکیده
منابع مشابه
Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.
PURPOSE Preexisting bone loss in men with prostate cancer is an important issue due to the accelerated bone loss during androgen deprivation therapy (ADT). In addition, a high prostate-specific antigen (PSA) level has been reported to be related to bone metabolism. This study assessed the factors associated with osteoporosis in Korean men with non-metastatic prostate cancer before undergoing AD...
متن کاملAndrogen-deprivation bone loss in patients with prostate cancer.
An increasing number of men with prostate cancer being treated with androgen-deprivation therapy (ADT) are at increased risk for developing osteoporosis. Osteoporosis often is overlooked in men and can have significant adverse economic effects and reduce quality of life, particularly if a fracture occurs. Nurses play a major role in identifying men who are at risk because of lifestyle factors a...
متن کاملBisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.
This systematic review was conducted to assess the efficacy and safety of bisphosphonates for prevention and treatment of osteopenia or osteoporosis in men with non-metastatic prostate cancer receiving androgen- deprivation therapy. We searched for randomised controlled trials (RCTs) of bisphosphonates compared with placebo from Pubmed, Embase, the Cochrane Library, and ISI - Science Citation I...
متن کاملBone health management in prostate cancer patients receiving androgen deprivation therapy.
PURPOSE Patients receiving androgen deprivation therapy undergo a rapid decline in bone mineral density during the first 6 to 12 months of initiating therapy. The World Health Organization has developed and implemented the Fracture Risk Assessment Tool (FRAX) to predict the ten year risk of a major fracture & hip fracture. Additionally, the National Comprehensive Cancer Network and the National...
متن کاملAndrogen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.
Androgen-deprivation therapy (ADT) has become a standard of care in the management of advanced prostate cancer or as an adjunct therapy. However, ADT is associated with a well-known deleterious effect on bone health, resulting in a decrease in bone-mass density (BMD) and increased risk for fracture. With the longer life expectancy of prostate cancer patients, improvement of the quality of life ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2018
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy284.054